Nephrology

According to the results, individuals with SCT who previously had COVID-19 also had various preexisting kidney conditions that were associated with poor outcomes.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Dr. Miriam Vos details the TARGET-NASH study, which indicated a higher prevalence of NAFLD in pediatric patients than previously thought.

The VersiPD Cycler System is expected to be available in the US in 2022.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

No specific inflammatory pathway was considered causative to long-term mortality in kidney transplant recipients.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

Team-based care shows the reduction of multiple risk factors, attainment of multiple treatment targets, and empowerment among high-risk patients with DKD.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

When combined with corticosteroids, the oral therapy appeared to be as effective as IVCY with a more favorable safety profile.

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

The phase 3 trial was stopped following a formal interim assessment that met pre specified criteria for positive efficacy in patients with chronic kidney disease.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

The treatment was comparable to darbepoetin alfa in treating patients with chronic kidney disease who were not undergoing dialysis.

Patients who receive a solid organ transplant and develop CDI are at an increased risk for an acute kidney injury.

The adjusted change in 24-hour systolic blood pressure from baseline to 12 weeks was −11.0 mm Hg in the chlorthalidone group and −0.5 mm Hg in the placebo group.